Results 81 to 90 of about 584,093 (236)

DOCKING STUDY OF ALLICIN WITH SULFONYLUREA RECEPTOR 1, COMPLEX 1 AND PPARγ RECEPTOR ON INSULIN RESISTANCE [PDF]

open access: yes, 2018
Objective: Allicin is a potential type 2 antidiabetic. Sulfonylurea receptor 1 (SUR1), nikotinamida adina dinukleotida dehydrogenase (Complex 1) and peroxisome proliferator-activated receptors gamma (PPARγ) are known as important receptors responsible ...
Luliana, Sri   +2 more
core   +1 more source

Ceramides, Particularly Those Containing Very‐Long‐Chain Saturated Fatty Acids, Are Independently Associated With the Triglyceride–Glucose Index in European Individuals With Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The triglyceride–glucose (TyG) index is associated with insulin resistance and cardiovascular disease (CVD), but the underlying mechanisms remain unclear. As ceramides are implicated in both insulin resistance and CVD, we investigated the association between the TyG index and plasma ceramides in individuals with Type 2 diabetes (T2D ...
Laure Carpentier   +7 more
wiley   +1 more source

Metformin and Severe Post‐COVID‐19 Outcomes Among Individuals With Diabetes Mellitus

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims We evaluated the relationship between metformin, one of the most commonly prescribed medications for individuals with diabetes, and COVID‐19 sequelae. Materials and Methods We evaluated a retrospective cohort of individuals in the National Clinical Cohort Collaborative with Type 2 diabetes mellitus and COVID‐19 who were prescribed ...
Zachary B. Dozier   +148 more
wiley   +1 more source

The Sulfonylurea Receptor

open access: yesNippon Nōgeikagaku Kaishi, 1997
Nobuya INAGAKI, Susumu SEINO
openaire   +4 more sources

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

open access: yesInternal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos   +5 more
wiley   +1 more source

[Sulfonylurea receptors and their interaction with glimepiride].

open access: yesLikars'ka sprava, 2003
In the review, data are presented on glymepiride (amaril), a 3-d generation sulphanylamide. The drug interacts with receptors to sulphonylurea--SUR X, that are found only in B-cells of the pancreas, which fact has been shown to be associated with a higher secretion of insulin, an increased sensitivity of peripheral tissues to this hormone and with ...
N A, Zueva, N V, Sologub, A S, Efimov
openaire   +1 more source

Phylogenetic tree of NBDs1 from subfamily ABCC.

open access: yes, 2014
Red, C. populi (Cp); blue, H. sapiens (Hs); black, T. castaneum (Tc). HsABC8 and 9 are sulfonylurea receptors (SUR); *, T. castanaeum with phenotype after RNAi. Numbers at nodes represent bootstrap values.
Ding Wang (191462)   +6 more
core   +1 more source

Diabetes attenuates weight reduction‐mediated liver fibrosis regression in persons with morbid obesity

open access: yesJournal of Diabetes Investigation, EarlyView.
ABSTRACT Aims Weight loss by laparoscopic sleeve gastrectomy (LSG) compared to medical weight loss (low‐calorie diet: LCD) ameliorates diabetes and metabolic dysfunction‐associated steatotic liver disease (MASLD). We aimed to evaluate changes in liver pathology 1‐year after LSG and their associations with metabolic factors in Japanese participants with
Daiki Matsubara   +11 more
wiley   +1 more source

Structure-activity relationships for a new family of sulfonylurea herbicides

open access: yes, 2005
Acetohydroxyacid synthase (AHAS; EC 2.2.1.6) catalyzes the first common step in branched-chain amino acid biosynthesis. The enzyme is inhibited by several chemical classes of compounds and this inhibition is the basis of action of the sulfonylurea and ...
Lee, Yu-Ting   +8 more
core   +1 more source

History of gastrointestinal symptoms with other glucose‐lowering agents is associated with gastrointestinal adverse events after imeglimin initiation: A retrospective real‐world study

open access: yesJournal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Imeglimin is an oral antidiabetic agent with a novel mechanism of action. Gastrointestinal (GI) adverse events (AEs) have been reported during imeglimin therapy. However, the factors associated with the occurrence of GI AEs have not been fully elucidated. This study aimed to investigate the incidence of GI AEs and the factors
Kodai Yoshida   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy